Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy

Non-Hodgkin’s lymphoma (NHL) represents a heterogeneous group of malignancies with high diversity in terms of biology, clinical responses, and prognosis. Standard therapy regimens produce a 5-year relative survival rate of only 69%, with the critical need to increase the treatment-success rate of th...

Full description

Bibliographic Details
Main Authors:	Perna, Serena Kimi, Huye, Leslie E, Savoldo, Barbara
Format:	Online
Language:	English
Published:	Dove Medical Press 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918257/

id	pubmed-4918257
recordtype	oai_dc
spelling	pubmed-49182572016-07-28 Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy Perna, Serena Kimi Huye, Leslie E Savoldo, Barbara Review Non-Hodgkin’s lymphoma (NHL) represents a heterogeneous group of malignancies with high diversity in terms of biology, clinical responses, and prognosis. Standard therapy regimens produce a 5-year relative survival rate of only 69%, with the critical need to increase the treatment-success rate of this patient population presenting at diagnosis with a median age of 66 years and many comorbidities. The evidence that an impaired immune system favors the development of NHL has opened the stage for new therapeutics, and specifically for the adoptive transfer of ex vivo-expanded antigen-specific T-cells. In this review, we discuss how T-cells specific for viral-associated antigens, nonviral-associated antigens expressed by the tumor, T-cells redirected through the expression of chimeric antigen receptors, and transgenic T-cell receptors against tumor cells have been developed and used in clinical trials for the treatment of patients with NHLs. Dove Medical Press 2015-03-19 /pmc/articles/PMC4918257/ /pubmed/27471712 http://dx.doi.org/10.2147/ITT.S31389 Text en © 2015 Perna et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Perna, Serena Kimi Huye, Leslie E Savoldo, Barbara
spellingShingle	Perna, Serena Kimi Huye, Leslie E Savoldo, Barbara Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy
author_facet	Perna, Serena Kimi Huye, Leslie E Savoldo, Barbara
author_sort	Perna, Serena Kimi
title	Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy
title_short	Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy
title_full	Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy
title_fullStr	Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy
title_full_unstemmed	Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy
title_sort	management of patients with non-hodgkin’s lymphoma: focus on adoptive t-cell therapy
description	Non-Hodgkin’s lymphoma (NHL) represents a heterogeneous group of malignancies with high diversity in terms of biology, clinical responses, and prognosis. Standard therapy regimens produce a 5-year relative survival rate of only 69%, with the critical need to increase the treatment-success rate of this patient population presenting at diagnosis with a median age of 66 years and many comorbidities. The evidence that an impaired immune system favors the development of NHL has opened the stage for new therapeutics, and specifically for the adoptive transfer of ex vivo-expanded antigen-specific T-cells. In this review, we discuss how T-cells specific for viral-associated antigens, nonviral-associated antigens expressed by the tumor, T-cells redirected through the expression of chimeric antigen receptors, and transgenic T-cell receptors against tumor cells have been developed and used in clinical trials for the treatment of patients with NHLs.
publisher	Dove Medical Press
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918257/
_version_	1613598694281576448

Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy

Similar Items